logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9731001 B1

PDFFull Text
Date of Patent:
Aug. 15, 2017

Filed:

Dec. 20, 2012

Three-dimensional cavities of dendritic cell immunoreceptor (dcir), compounds binding thereto and therapeutic applications related to inhibition of human immunodeficiency virus type-1 (hiv-1)

Applicant:

Universite Laval, Quebec, CA;

Inventors:

Caroline Gilbert, St-Augustin de Desmaures, CA;

Michel J. Tremblay, Quebec, CA;

Sheng-Xiang Lin, Ste-Foy, CA;

Arezki Azzi, Riyadh, SA;

Alexandra Lambert, Quebec, CA;

Assignee:

Universite Laval, Quebec, CA;

Attorneys:

Choate, Hall & Stewart LLP

Brenda Herschbach Jarrell

Michael L. Vetter

Primary Examiner:

Raymond Henley, III

Int. Cl.
CPC ...
A61K 31/40 (2006.01); A61K 31/34 (2006.01); A61K 31/13 (2006.01); A61K 39/21 (2006.01); A61K 31/12 (2006.01); A61K 31/343 (2006.01); A61K 31/352 (2006.01); A61K 31/404 (2006.01); A61K 31/41 (2006.01); A61K 31/4245 (2006.01); A61K 31/427 (2006.01); A61K 31/428 (2006.01); A61K 31/4439 (2006.01); A61K 31/47 (2006.01); A61K 31/501 (2006.01); A61K 31/655 (2006.01); C40B 30/02 (2006.01); C07K 14/705 (2006.01); C07C 49/796 (2006.01); C07C 291/08 (2006.01); C07D 215/58 (2006.01); C07D 257/04 (2006.01); C07D 271/12 (2006.01); C07D 277/64 (2006.01); C07D 307/79 (2006.01); C07D 307/80 (2006.01); C07D 311/82 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 405/06 (2006.01); C07D 417/14 (2006.01);
U.S. Cl.
CPC ...
A61K 39/21 (2013.01); A61K 31/12 (2013.01); A61K 31/343 (2013.01); A61K 31/352 (2013.01); A61K 31/404 (2013.01); A61K 31/41 (2013.01); A61K 31/427 (2013.01); A61K 31/428 (2013.01); A61K 31/4245 (2013.01); A61K 31/4439 (2013.01); A61K 31/47 (2013.01); A61K 31/501 (2013.01); A61K 31/655 (2013.01); C07C 49/796 (2013.01); C07C 291/08 (2013.01); C07D 215/58 (2013.01); C07D 257/04 (2013.01); C07D 271/12 (2013.01); C07D 277/64 (2013.01); C07D 307/79 (2013.01); C07D 307/80 (2013.01); C07D 311/82 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/06 (2013.01); C07D 417/14 (2013.01); C07K 14/7056 (2013.01); C40B 30/02 (2013.01);
Abstract

The invention is concerned with compounds, pharmaceutical compositions, screening methods, and therapeutic methods for preventing or reducing a human immunodeficiency virus type-1 (HIV-1) infection and/or propagation associated with dendritic cell immunoreceptor (DCIR). Described herein are compounds which bind on at least one three-dimensional cavity of the DCIR, the cavity(ies) being involved in the interaction between HIV-1 and DCIR. Also described are screening methods for identifying active inhibitors and method of using such inhibitors for the prevention or treatment of virus infections, and more particularly for reducing human immunodeficiency virus type-1 (HIV-1) binding, entry and/or replication in human cells.

Find Patent Forward Citations

Loading…